Chai Discovery has successfully raised $400 million, boosting its valuation to $3.4 billion within just two years. The biotech startup, which specializes in AI-driven drug discovery, has garnered backing from major players in the pharmaceutical industry, including Pfizer and Eli Lilly.

Funding and Growth Milestones

Founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud, Chai Discovery began its journey with a seed investment of approximately $30 million. Following this, it secured $70 million in a Series A round in August 2025 and $130 million in Series B financing in December 2025, which established its initial valuation at $1.3 billion. This latest funding round marks a significant leap, nearly tripling the company’s valuation.

Innovative Drug Discovery Technology

The company’s proprietary Chai-2 model is capable of designing novel antibodies from the ground up, achieving hit rates of around 20%. This figure starkly contrasts with the approximately 0.1% hit rates of previous computational methods, making Chai Discovery's approach approximately 200 times more effective in identifying viable drug candidates. Mikael Dolsten, the former Chief Scientific Officer at Pfizer, has joined Chai Discovery's board, further solidifying the company’s credibility in the pharmaceutical sector.

Chai Discovery's trajectory raises important questions regarding the role of decentralization and blockchain technology in drug discovery, especially as it thrives without them. The company’s success suggests traditional venture capital and corporate partnerships remain key in the drug development landscape. With significant investments pouring into AI applications, major institutions are increasingly viewing AI-driven drug discovery as a crucial extension of their existing technology rather than a domain necessitating blockchain integration.

Comparatively, platforms like VitaDAO operate on a vastly different scale, presenting a contrast to the hundreds of millions directed toward companies like Chai Discovery. Should Chai Discovery's 20% hit rate stand up to clinical validation, it may challenge the narrative for blockchain-based solutions in institutional funding.

This material is for informational purposes only and should not be considered as financial advice.